European Medicines Agency recommends a variation to the terms of the marketing authorisation for panitumumab

The change concerns first-line combination treatment with FOLIFIRI.

• On 26 February 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product panitumumab (Vectibix).  Read more here.